148 related articles for article (PubMed ID: 16119008)
1. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Yano S; Nakataki E; Ohtsuka S; Inayama M; Tomimoto H; Edakuni N; Kakiuchi S; Nishikubo N; Muguruma H; Sone S
Oncol Res; 2005; 15(2):107-11. PubMed ID: 16119008
[TBL] [Abstract][Full Text] [Related]
2. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
3. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
6. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
9. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
[TBL] [Abstract][Full Text] [Related]
11. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
[TBL] [Abstract][Full Text] [Related]
12. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
[TBL] [Abstract][Full Text] [Related]
14. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
[TBL] [Abstract][Full Text] [Related]
15. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
Yoshimoto A; Inuzuka K; Kita T; Kawashima A; Kasahara K
Am J Med Sci; 2007 Apr; 333(4):221-5. PubMed ID: 17435415
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
[TBL] [Abstract][Full Text] [Related]
17. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE
Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
[TBL] [Abstract][Full Text] [Related]
20. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
